Skip navigation

Interpret Changing Guidelines • Strengthen Compliance Programs • Prepare for Inspections

June 19-20, 2019
  • Washington, DC

As the industry faces increasingly intense scrutiny from regulators, compounding pharmacies must quickly adapt to comply with new and updated guidelines and prepare for more frequent inspection. CBI’s Compounding Pharmacy Compliance brings together industry leaders to break down these complex guidelines and discover best practices for compliance through two concurrent tracks addressing the unique challenges faced by 503A and 503B compounding facilities. This program provides the opportunity to engage with expert faculty and like-minded peers to ensure you are prepared to navigate this rapidly-shifting landscape, including Pharmacy State Board, USP, and cGMP guidelines, and strategies for preparing for and responding to FDA inspections.

What are the top benefits of attending?

  • Understand the nuances of updated and upcoming regulatory guidelines
  • Hear FDA, NABP, and industry perspectives on developing integrated quality and compliance programs
  • Implement best practices for preparing for inspections and responding to 483 letters
  • Prepare your facility to comply with USP or cGMP standards
  • Discover new monitoring, testing, and validation solutions
  • Learn to proactively engage with regulators
  • Collaborate with peers and share solutions to common issues

Previous Attendee Acclaim:

I was delighted to hear the speakers at the conference. They were 100% open and willing to share their vast experiences with the group. It's great to hear from the FDA and others in a collaborative environment. Congratulations on a successful conference!

Quality Assurance Manager  KRS Global Biotechnology

Overall, well run and informative. Speakers were knowledgeable… and learned information that can be applied to current practice

Owner  Harbor Compounding Pharmacy

Opportunities for networking with colleagues in 503B space are limited. Thank you for providing this forum for learning and interacting

Director of Corporate Quality  SCA Pharmaceuticals

Compounding Pharmacy Compliance

Interpret Changing Guidelines • Strengthen Compliance Programs • Prepare for Inspections

As the industry faces increasingly intense scrutiny from regulators, compounding pharmacies must quickly adapt to comply with new and updated guidelines and prepare for more frequent inspection. CBI’s Compounding Pharmacy Compliance brings together industry leaders to break down these complex guidelines and discover best practices for compliance through two concurrent tracks addressing the unique challenges faced by 503A and 503B compounding facilities. This program provides the opportunity to engage with expert faculty and like-minded peers to ensure you are prepared to navigate this rapidly-shifting landscape, including Pharmacy State Board, USP, and cGMP guidelines, and strategies for preparing for and responding to FDA inspections.

What are the top benefits of attending?

  • Understand the nuances of updated and upcoming regulatory guidelines
  • Hear FDA, NABP, and industry perspectives on developing integrated quality and compliance programs
  • Implement best practices for preparing for inspections and responding to 483 letters
  • Prepare your facility to comply with USP or cGMP standards
  • Discover new monitoring, testing, and validation solutions
  • Learn to proactively engage with regulators
  • Collaborate with peers and share solutions to common issues

Previous Attendee Acclaim:

I was delighted to hear the speakers at the conference. They were 100% open and willing to share their vast experiences with the group. It's great to hear from the FDA and others in a collaborative environment. Congratulations on a successful conference!

Quality Assurance Manager  KRS Global Biotechnology

Overall, well run and informative. Speakers were knowledgeable… and learned information that can be applied to current practice

Owner  Harbor Compounding Pharmacy

Opportunities for networking with colleagues in 503B space are limited. Thank you for providing this forum for learning and interacting

Director of Corporate Quality  SCA Pharmaceuticals